Positive Patient Outcomes Data on Inspire Therapy Highlighted at Sleep 2016

Download as PDF

Patient Outcomes Data Demonstrating the Effectiveness of Inspire Therapy Presented
at SLEEP 2016, the 30th Annual Joint Meeting of the American Academy of Sleep
Medicine and the Sleep Research Society in Denver

MINNEAPOLIS (June 21, 2016) — Inspire Medical Systems, Inc., today announced
the highlights of clinical data presented at the 30th Annual SLEEP Meeting, held June
11-15 in Denver, Colorado. Over the course of the five-day medical congress, Inspire
therapy was featured in several poster/oral presentations and two educational
symposia discussing further clinical assessments of the sleep apnea device from
academic institutions in the United States and Germany.

Among the presentations were three that included additional clinical evidence for
patients implanted with Inspire therapy and one that included further long-term
data from the Stimulation Therapy for Apnea Reduction (STAR) trial. Each study
supports the fact that Inspire therapy is an adjustable, titratable medical device that
decreases the burden of moderate to severe obstructive sleep apnea in those
patients unable to get consistent benefit from CPAP.

One multi-center clinical study led by Dr. Maurits Boon, Co-Director of the Voice and
Swallowing Center at Thomas Jefferson University Hospital in Philadelphia, and
presented by Dr. Colin Huntley, also of Thomas Jefferson University Hospital,
discussed the results of the first 65 patients implanted with the Inspire device at
Thomas Jefferson University Hospital and the University of Pittsburgh Medical
Center. The presentation, entitled, “Upper Airway Stimulation: Initial Experience and
Outcomes at Two Academic Centers” concluded that there were statistically
significant reductions in the Apnea-Hypopnea Index (AHI) and improvements in
patients’ oxygen saturation levels. Using the standard SHER success criteria, the
sites reported a 94% therapy success rate. Further, 79% of patients experienced a
reduction to less than 10 events/hour deemed to be a clinically relevant reduction
in AHI.

“This implanted neurostimulation therapy is a successful surgical option, and the
positive results are reproducible between high volume medical centers. We will
continue to follow our patients to evaluate for longevity of success,” stated Dr.
Maurits Boon.

Another oral presentation at SLEEP 2016 was delivered by Dr. Clemens Heiser of
the Technische Universität München in Munich, Germany. His discussion, “Selective
Upper Airway Stimulation – German Post Market Study” covered the results from a
multi-center, post-market clinical study that detailed the outcomes of 61 patients
implanted with Inspire therapy in three German medical centers; one each in
Munich, Mannheim and Lübeck. This study used home sleep testing for baseline-
screening and 6-month follow-ups for objective outcome measurement. The results
demonstrated an average AHI reduction of almost 70% in those patients and an
average device utilization of 43 hours per week. The study concluded that selective
Inspire therapy is a safe and effective treatment for patients with moderate to
severe OSA and represents a substantial innovation in the treatment variety for OSA
patients.

A third oral presentation entitled, “Hypoglossal Nerve Stimulation for OSA: Initial
Results at the University of Pennsylvania”, was delivered by Dr. Richard J. Schwab of
the Department of Pulmonology at the University of Pennsylvania. Dr. Schwab’s
study focused on the clinical results of patients with severe obstructive sleep apnea
who were implanted with Inspire therapy. The group of twenty patients studied
had statistically significant improvements in their AHI, with the median total AHI for
20 patients after implant at 2.1 events/hour and a median decrease of 37.7
events/hour (changes ranging from -66.4 to 11.3). Dr. Schwab concluded, “Overall,
patients that elected to undergo the device implant surgery at UPenn showed a
significant improvement in their sleep apnea severity based on total AHI. These
preliminary data show an overall positive response to treatment and support
continued use of the device for patients with obstructive sleep apnea.”

Finally, Dr. Jason Cornelius of the Minneapolis Clinic of Neurology presented an
update for the STAR Trial entitled, “Durability of Stimulation Thresholds and Therapy
Programming at 36 and 42 months.” This study supports the hypothesis that
stimulation thresholds show long-term stability. Therapeutic stimulation
amplitudes and patient-specific stimulation thresholds through 30-months post
implant were previously reported and found to be stable. The 36-month and 42-
month thresholds continue to be stable, and minimal stimulation programming
changes were made at follow-up. The data show that following in-lab titration, long
term care can be managed by physician-directed follow up in the clinic.

“The clinical experience and therapy adoption of Inspire therapy continue to grow
at very impressive rates,” reports Tim Herbert, President and CEO of Inspire Medical
Systems, Inc. “The clinical evidence presented at SLEEP 2016 is important in that it
represents several independent positive evaluations of the therapy by leading
medical centers in the United States and Germany.”

These presentations and others at SLEEP 2016 underscore the benefits of Inspire
therapy, demonstrating significant and sustained reductions in objective and
subjective clinical outcomes. Inspire Medical is anticipating that more data will be
presented at the upcoming American Academy of Otolaryngology – Head and Neck
Surgery Foundation (AAO-HNSF) annual meeting to be held in San Diego, California
on September 18 – 21.

About Inspire Therapy
Untreated Obstructive Sleep Apnea (OSA) can have devastating effects on heart and
brain health, impair quality of life, and increase accident risk. Inspire Upper Airway
Stimulation (UAS) therapy is an FDA-approved treatment for some people with
moderate to severe OSA who are unable to tolerate or get relief from continuous
positive airway pressure (CPAP). In contrast to CPAP, Inspire therapy is implanted
inside the body and works with a patient’s natural breathing process. Controlled by
the patient sleep remote, the system includes a breathing sensor and a stimulation
lead powered by a small battery. During sleep, the system senses breathing patterns
and delivers mild stimulation to the tongue and other soft tissues of the throat to
keep the airway open. Inspire therapy is currently available at more than 100
leading medical centers across the United States and Europe.

About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc., based in Minneapolis, Minn., was incorporated in
2007 with the sole purpose of developing a safe, effective and well-accepted therapy
to help those OSA patients who are unable to tolerate or get relief from CPAP.
Inspire therapy is the world’s first implantable FDA-approved neurostimulation
system for the treatment of OSA. The Company is privately held and investors
include Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner
Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science
Partners, TGap Ventures and US Venture Partners.

For more information, visit www.InspireSleep.com.

Media Contact: Howard Green
howardgreen@inspiresleep.com
651-357-3616